Development of cost effective biodegradable implants of ciprofloxacin hydrochloride in treatment of osteomyelitis

Ashish Y Pawar, Deelip V Derle


In the present study, an attempt has been made to formulate and evaluate a sustained release implant of ciprofloxacin HCl with biodegradable, cost‐effective polymer chitosan. osteomyelitis is one of the oldest disease, which is still in existence and difficult to treat, the prevalence of which is increasing day‐by‐day. The treatment of osteomyelitis requires large doses of antibiotics administered by systemic routes for a period of 4‐5 weeks, however, the parenteral route suffered from many disadvantages and also some limitations. Ciprofloxacin hydrochloride has been the most widely used fluoroquinolone for multi‐bacterial bone infection because the minimal inhibitory concentration of ciprofloxacin HCl is low, and it has good penetration properties in most of the tissues and bone. Biodegradable polymers like poly (lactic‐co‐glycolic acid) (PLGA) and Polycaprolactone (PCL) were widely studied as a carrier for implant but their use is limited because of high‐cost and are not easily available. The cross‐linking of chitosan was carried out with sodium citrate and cross‐linked chitosan (CC) was used as a carrier. The effect of different proportion of chitosan and effect of drug loading on the drug release kinetics has been studied. An in vitro result shows that prolonged release was observed with higher drug loading. The CC5 implant containing 50% w/w polymer retards the drug release for more than 5 weeks. Furthermore, from in vivo study it is found that the optimized formulation CC5 is biocompatible and implant is not causing any foreign body reaction or hypersensitivity in the body of animal. The CC was found to have excellent release retarding properties and can be used as cost‐effective,biodegradable sustained release matrices for designing of implant.

Full Text:



Tanaka KS, Houghton TJ, Kang T, Dietrich E, Delorme D, Ferreira SS, et al.

Bis‐phosphonated fluoroquinolone esters as osteotropic prodrugs for

the prevention of osteomyelitis. Bioorg Med Chem 2008;16:9217‐29.

Zimmerli W, Trampuz A, Ochsner PE. Prosthetic‐joint infections. N Engl

J Med 2004;351:1645‐54.

Lazzarini L, Mader JT, Calhoun JH. Osteomyelitis in long bones. J Bone

Joint Surg Am 2004;86‐A:2305‐18.

Wolter K. Professional Guide to Diseases. 8th ed. Lippincott Williams

and Wilkins, New York,; 2005. p. 234‐5.

Tavakoli M, Davey P, Clift BA, Davies HT. Diagnosis and management

of osteomyelitis. Pharmacoeconomics 1999;16:627‐47.

Rodrigo SV, Marisa M. Interaction of natural and crosslinked chitosan

membranes with Hg (II) ions. Colloids and Surfaces A. Physicochem

Engg Aspects 2006;279:196‐207.

Beppu MM, Vieira RS, Aimoli CG, Santana CC. Crosslinking of chitosan

membranes using glutaraldehyde: Effect on ion permeability and water

absorption. J Memb Sci 2007;301:126‐30.

Shu XZ, Zhu KJ, Song W. Novel pH‐sensitive citrate cross‐linked chitosan

film for drug controlled release. Int J Pharm 2001;212:19‐28.

Rana V, Babita K, Goyal D, Tiwary A. Sodium citrate cross‐linked chitosan

films: Optimization as substitute for human/rat/rabbit epidermal sheets.

J Pharm Pharm Sci 2004;8:10‐7.

Jaleh V. Effect of citric acid as cross‐linking agent on insulin loaded

chitosan microspheres. Iranian Polymer Journal 2005;14:647‐56.

Chen S, Liu M, Jin S, Wang B. Preparation of ionic‐crosslinked

chitosan‐based gel beads and effect of reaction conditions on drug

release behaviors. Int J Pharm 2008;349:180‐7.

Baro M, Sánchez E, Delgado A, Perera A, Evora C. In vitro‐in vivo

characterization of gentamicin bone implants. J Control Release


Désévaux C, Dubreuil P, Lenaerts V. Characterization of crosslinked

high amylose starch matrix implants. 1. In vitro release of ciprofloxacin.

J Control Release 2002;82:83‐93.

Castro C, Sánchez E, Delgado A, Soriano I, Núñez P, Baro M,

et al. Ciprofloxacin implants for bone infection. In vitro‐in vivo

characterization. J Control Release 2003;93:341‐54.

Siewert M, Dressman J, Brown CK, Shah VP, FIP, AAPS. FIP/AAPS

guidelines to dissolution/in vitro release testing of novel/special dosage

forms. AAPS Pharm Sci Tech 2003;4 (1)1‐10.

Lim Soo P, Cho J, Grant J, Ho E, Piquette‐Miller M, Allen C. Drug release

mechanism of paclitaxel from a chitosan‐lipid implant system: Effect

of swelling, degradation and morphology. Eur J Pharm Biopharm


Désévaux C, Lenaerts V, Girard C, Dubreuil P. Characterization of

crosslinked high amylose starch matrix implants. 2. In vivo release of

ciprofloxacin. J Control Release 2002;82:95‐103.



  • There are currently no refbacks.